A Feasibility Study of the Nativis Voyager® System in Patients With Recurrent Glioblastoma Multiforme (GBM)
Public ClinicalTrials.gov record NCT02296580. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This feasibility study will assess the effects of the Nativis Voyager therapy in patients with first or second recurrence of GBM who have either failed standard of care or are intolerant to therapy. The study will enroll and treat up to 32 subjects with Voyager plus lomustine with or without bevacizumab. Safety and clinical utility will be evaluated.
Study identification
- NCT ID
- NCT02296580
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Not applicable
- Enrollment
- 37 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 2014 (Actual)
- Primary completion
- Sep 30, 2021 (Actual)
- Completion
- Sep 30, 2021 (Actual)
- Last update posted
- Feb 2, 2023
2014 – 2021
United States locations
- U.S. sites
- 12
- U.S. states
- 9
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham (UAB) | Birmingham | Alabama | 35233 | — |
| Center for Neurosciences | Tucson | Arizona | 85718 | — |
| cCARE - California Cancer Associates for Research & Excellence | Encinitas | California | 92024 | — |
| John Wayne Cancer Institute @ Providecne St. Johns Health Center | Santa Monica | California | 90404 | — |
| Associated Neurologists of Southern CT, P.C. | Fairfield | Connecticut | 06824 | — |
| Boca Raton Regional Hospital | Boca Raton | Florida | 33486 | — |
| University of Kansas Medical Center (KUMC) | Kansas City | Kansas | 66205 | — |
| Providence Brain & Spine Institute | Portland | Oregon | 97225 | — |
| Cancer Care Collaborative | Austin | Texas | 78705 | — |
| Baylor Scott & White Health | Temple | Texas | 76508 | — |
| Virginia Mason Hospital & Medical Center | Seattle | Washington | 98101 | — |
| Swedish Medical Center | Seattle | Washington | 98122 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02296580, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 2, 2023 · Synced Nov 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02296580 live on ClinicalTrials.gov.